<DOC>
	<DOCNO>NCT01319357</DOCNO>
	<brief_summary>Diabetes mellitus metabolic disease grow prevalence worldwide . Currently available therapy type 2 diabetes various limitation associate increase risk hypoglycemia , weight gain , gastrointestinal side effect edema heart failure . A new promising class drug gliptins . Several efficacy study demonstrate significant improvement HbA1c gliptins . In addition , gliptins improved fasting well prandial glucose level induce weight gain . Due positive metabolic effect combination small spectrum side effect gliptins might well part standard therapy type 2 diabetes future . Apart form surrogate parameter like reduction fast postprandial blood glucose level improvement HbA1c , effect gliptins micro- macrovascular function cardiovascular outcome primary focus current study . Diabetes mellitus strongly associate microangiopathy macroangiopathy strong independent risk factor cardiovascular disease cardiovascular mortality . Endothelial dysfunction play crucial role atherosclerotic process commonly observe patient diabetes mellitus already prediabetes - amongst factor - link fasting postprandial hyperglycemia . Taken account gliptins reduce hyperglycemia hyperglycemic peak prevent inactivation GLP-1 , exert beneficial effect endothelium previous study major interest whether therapy gliptins improve endothelial function .</brief_summary>
	<brief_title>Effects Saxagliptin Endothelial Function</brief_title>
	<detailed_description>Diabetes mellitus metabolic disease grow prevalence worldwide , affect 171 million people 2000 expect 366 million people 2030 [ 1 ] .. Currently available therapy type 2 diabetes various limitation associate increase risk hypoglycemia , weight gain , gastrointestinal side effect edema heart failure . A new promising class drug gliptins . Gliptins act inhibit enzyme dipeptidyl peptidase-4 ( DPP-4 ) , responsible rapid inactivation glucagon-like peptide-1 ( GLP-1 ) - incretin hormone gut [ 2-4 ] , thereby enhance prolong effect GLP-1 . GLP-1 - member incretin hormone - release blood meal ingestion stimulate insulin secretion glucose dependent manner . This account marked prandial insulin response , prevent prandial hyperglycemia . Several efficacy study demonstrate significant improvement HbA1c gliptins . In addition , gliptins improved fasting well prandial glucose level induce weight gain . Due positive metabolic effect combination small spectrum side effect gliptins might well part standard therapy type 2 diabetes future . Apart form surrogate parameter like reduction fast postprandial blood glucose level improvement HbA1c , effect gliptins micro- macrovascular function cardiovascular outcome primary focus current study . However , infusion GLP-1 , incretin hormone affect gliptins report ameliorate endothelial dysfunction patient suffer coronary artery disease [ 5 ] recently show infusion GLP-1 healthy human subject increase normal ACh-induced vasodilatation [ 6 ] . In study rat diabetes , GLP-1 infusion nearly re-established normal vascular tone [ 7 ] data experimental animal indicate beneficial effect GLP-1 endothelial function [ 8 ] . Diabetes mellitus strongly associate microangiopathy macroangiopathy strong independent risk factor cardiovascular disease cardiovascular mortality [ 9 ] . Endothelial dysfunction play crucial role atherosclerotic process commonly observe patient diabetes mellitus already prediabetes - amongst factor - link fasting postprandial hyperglycemia . Taken account gliptins reduce hyperglycemia hyperglycemic peak prevent inactivation GLP-1 , exert beneficial effect endothelium previous study major interest whether therapy gliptins improve endothelial function micro- macrovasculature thereby might prove affect cardiovascular morbidity mortality diabetic patient long term . The retina offer unique opportunity directly visualize investigate microvasculature vivo [ 10-14 ] . References 1 . Wild S , Roglic G , Green A , Sicree R , King H : Global prevalence diabetes : Estimates year 2000 projection 2030 . Diabetes Care 2004 ; 27:1047-1053 . 2 . Deacon CF , Ahren B , Holst JJ : Inhibitors dipeptidyl peptidase iv : A novel approach prevention treatment type 2 diabetes ? Expert Opin Investig Drugs 2004 ; 13:1091-1102 . 3 . Deacon CF : Therapeutic strategy base glucagon-like peptide 1 . Diabetes 2004 ; 53:2181-2189 . 4 . Holst JJ , Deacon CF : Glucagon-like peptide-1 mediates therapeutic action dpp-iv inhibitor . Diabetologia 2005 ; 48:612-615 . 5 . Nystrom T , Gutniak MK , Zhang Q , Zhang F , Holst JJ , Ahren B , Sjoholm A : Effects glucagon-like peptide-1 endothelial function type 2 diabetes patient stable coronary artery disease . Am J Physiol Endocrinol Metab 2004 ; 287 : E1209-1215 . 6 . Basu A , Charkoudian N , Schrage W , Rizza RA , Basu R , Joyner MJ : Beneficial effect glp-1 endothelial function human : Dampening glyburide glimepiride . Am J Physiol Endocrinol Metab 2007 ; 293 : E1289-1295 . 7 . Ozyazgan S , Kutluata N , Afsar S , Ozdas SB , Akkan AG : Effect glucagon-like peptide-1 ( 7-36 ) exendin-4 vascular reactivity streptozotocin/nicotinamide-induced diabetic rat . Pharmacology 2005 ; 74:119-126 . 8 . Yu M , Moreno C , Hoagland KM , Dahly A , Ditter K , Mistry M , Roman RJ : Antihypertensive effect glucagon-like peptide 1 dahl salt-sensitive rat . J Hypertens 2003 ; 21:1125-1135 . 9 . Laakso M : Hyperglycemia cardiovascular disease type 2 diabetes . Diabetes 1999 ; 48:937-942 . 10 . Delles C , Michelson G , Harazny J , Oehmer S , Hilgers KF , Schmieder RE : Impaired endothelial function retinal vasculature hypertensive patient . Stroke 2004 ; 35:1289-1293 . 11 . Harazny JM , Ritt M , Baleanu D , Ott C , Heckmann J , Schlaich MP , Michelson G , Schmieder RE : Increased wall : Lumen ratio retinal arteriole male patient history cerebrovascular event . Hypertension 2007 ; 50:623-629 . 12 . Ritt M , Schmieder RE : Wall-to-lumen ratio retinal arteriole tool assess vascular change . Hypertension 2009 ; 54:384-387 . 13 . Oehmer S , Harazny J , Delles C , Schwarz T , Handrock R , Michelson G , Schmieder RE : Valsartan retinal endothelial function elderly hypertensive patient . Blood Press 2006 ; 15:185-191 . 14 . Ott C , Schlaich MP , Harazny J , Schmidt BM , Michelson G , Schmieder RE : Effects angiotensin ii type 1-receptor blockade retinal endothelial function . J Hypertens 2008 ; 26:516-522 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus define fast glucose ≥126 mg/dl HbA1c ≥6.5 % blood glucose lower medication Age 18 75 year Male Female patient eligible . Females child bear potential within two year menopause eligible pregnancy test screen visit negative use adequate contraceptive precaution trial . The patient must demonstrate she/he able willing perform blood glucose measurement necessary Home Blood Glucose Monitoring herself/himself demonstrate her/him . Any form diabetes mellitus type 2 diabetes mellitus Patients one blood glucose lower medication insulin therapy Last measured HbA1c &gt; 11 % Blood pressure level ≥180/110 mmHg Body mass index &gt; 50 kg/m² Triglyceride level &gt; 1000 mg/dl HDLcholesterol level &lt; 25 mg/dl Estimated creatinine clearance &lt; 50 ml/min/1.73m² Macroalbuminuria define urinary albuminetocreatinine ratio &gt; 300 mg/g Known liver function test &gt; 3 time upper limit normal Pregnant breastfeeding patient Current previous ( within 6 month ) treatment incretinbased therapy DPP 4 inhibitor and/or GLP1 mimetics Any patient currently receive chronic ( &gt; 30 consecutive day ) treatment oral corticosteroid Acute cardiovascular event ( include myocardial infarction , unstable angina pectoris , percutaneous coronary intervention , heart failure , stroke , TIA . PRIND , intracerebral bleeding ) &lt; 6 month prior screen visit ( visit 1 ) Diabetic retinopathy History epilepsia history seizures Patients treat severe auto immune disease e.g . lupus Involvement planning and/or conduct study ( applies AstraZeneca BMS representative staff and/or staff study site ) Previous randomisation present study Participation another clinical study within 30 day prior visit 1 Individuals risk poor protocol medication compliance Subject give write consent , pseudonymous data transfer line duty documentation duty notification accord § 12 § 13 GCPV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>